Name: UMIN ID:
Unique ID issued by UMIN | UMIN000035622 |
---|---|
Receipt number | R000040516 |
Scientific Title | A Multicenter Phase II study of Trastuzumab emtansine for non-small cell lung cancer positive for HER2 exon 20 insertion mutation. |
Date of disclosure of the study information | 2019/01/22 |
Last modified on | 2022/01/24 09:11:42 |
No. | Disposal | Last modified on | Item of update | |
---|---|---|---|---|
1 | Insert | 2019/01/22 15:52:06 | ||
2 | Update | 2019/02/06 15:25:44 | Institutions |
|
3 | Update | 2019/02/08 11:30:31 | Institutions |
|
4 | Update | 2019/02/28 11:12:25 | Recruitment status |
|
5 | Update | 2019/04/01 14:32:47 | 1st name of lead principal investigator Last name of lead principal investigator 1st name of lead principal investigator Last name of lead principal investigator Zip code Last name of contact person Last name of contact person Zip code Organization Organization Address Address Tel Institutions |
|
6 | Update | 2019/05/10 13:57:14 | Institutions |
|
7 | Update | 2019/05/29 10:28:08 | Institutions |
|
8 | Update | 2019/08/22 10:03:41 | Date of IRB Last follow-up date |
|
9 | Update | 2019/08/22 10:08:23 | Institutions |
|
10 | Update | 2020/01/22 11:13:47 | Secondary IDs Study ID_1 Org. issuing International ID_1 Org. issuing International ID_1 |
|
11 | Update | 2020/04/09 17:48:08 | UMIN ID1 |
|
12 | Update | 2020/04/23 16:04:10 | Organization Organization Division name Division name Address Address TEL Email1 |
|
13 | Update | 2020/07/28 11:20:13 | Recruitment status |
|
14 | Update | 2020/07/28 11:21:03 | Number of participants that the trial has enrolled |
|
15 | Update | 2021/07/26 08:49:50 | Date of closure to data entry Date trial data considered complete Date analysis concluded |
|
16 | Update | 2022/01/24 09:10:56 | Recruitment status |
|
17 | Update | 2022/01/24 09:11:42 | Publication of results Date of the first journal publication of results |